Human Blood Products

Added: Mar 22, 2017 2:37 pm Modified: Mar 23, 2017 12:48 pmTrack Changes RE: VA261-17-Q-0408, Amendment A00002, Human Blood Products

The following is the list of items and estimated quantities:



1 Leukocyte reduced Red Blood Cells (RBCs) 2,000

2 RBCs, Washed 25

3 RBCs, Irradiated 200

4 RBCs, Autologous 20

5 RBCs, Thawed 12

6 RBCs, Directed 6

7 Fresh Frozen Plasma (FFP) 900

8 Platelet, single donor (SD) Apheresis 500

9 Pooled Cryoprecipitate (Cryo) 75

10 Rh Immune Globulin (Rhlg) 2

11 Screening for Negative Blood per Antigen 100

12 Irradiated Units 400

13 Screening for Cytomegalovirus (CMV) Negative Blood 20

14 Antibody Identification 30

15 Enzyme Panel 20

16 Select Cell Panel 20

17 Absorption/Elution with Panel 15

18 Inhibition/Panel 5

19 Chloroquine Treatment 5

20 Extended Phenotyping 30

21 Phenotyping, Genotyping Whole Blood or Red Cell Mass 32

22 Plateletpheresis, Crossmatched 10

23 Screening for Historically Antigen Negative Blood per Antigen 200

24 Crossmatched Platelet Donor Recruitment 30

25 Transporation Surcharge for (Statim) STAT Orders 200

26 STAT Off Hours Surcharge 40

27 Volume-reduced cellular products 10

28 Dithiothreitol (DTT) Screen 25

29 DTT panel 10

30 RBC Genotype [Human Erytrocyte Antigen (HEA) BeadChip Assay or similar 5

31 Drug Study 5

32 Direct Antiglobulin Test 5

33 Adsorption Autologous (Auto) 15

34 Adsorption Allogeneic (Allo) 10

35 Adsorption Rabbit Erythrocyte Stroma (RESt) (Cold Auto) 5

36 ABO/Rh Grouping 5

37 Antibody Screen 5

38 Platelet Crossmatch (Test) 20

39 Plateletpheresis, HLA Matched 5

40 Platelet Antibody Screen 10

41 HLA Antibody Screen 10

42 Patient HLA (A,B) Typing for HLA Platelet Selection 10

43 HPA-1a Antigen Screen 1

44 Molecular Genotype (HPA) 1

Added: Mar 22, 2017 2:37 pm Modified: Mar 23, 2017 12:30 pmTrack Changes RE: VA261-17-Q-0408, Amendment A00001, Human Blood Products

The following is the list of items and estimated quantities: Estimated

Item Quantity

Number Item Description Per Year



1 Leukocyte reduced Red Blood Cells(RBCs) 2,000

2 RBCs, Washed 25

3 RBCs, Irradiated 200

4 RBCs, Autologous 20

5 RBCs, Thawed 12

6 RBCs, Directed 6

7 Fresh Frozen Plasma (FFP) 900

8 Platelet, single donor (SD) Apheresis 500

9 Pooled Cryoprecipitate (Cryo) 75

10 Rh Immune Globulin (Rhlg) 2

11 Screening for Negative Blood per Antigen 100

12 Irradiated Units 400

13 Screening for Cytomegalovirus (CMV) Negative Blood 20

14 Antibody Identification 30

15 Enzyme Panel 20

16 Select Cell Panel 20

17 Absorption/Elution with Panel 15

18 Inhibition/Panel 5

19 Chloroquine Treatment 5

20 Extended Phenotyping 30

21 Phenotyping, Genotyping Whole Blood or Red Cell Mass 32

22 Plateletpheresis, Crossmatched 10

23 Screening for Historically Antigen Negative Blood per Antigen 200

24 Crossmatched Platelet Donor Recruitment 30

25 Transporation Surcharge for (Statim) STAT Orders 200

26 STAT Off Hours Surcharge 40

27 Volume-reduced cellular products 10

28 Dithiothreitol (DTT) Screen 25

29 DTT panel 10

30 RBC Genotype [Human Erytrocyte Antigen (HEA) BeadChip Assay or similar 5

31 Drug Study 5

32 Direct Antiglobulin Test 5

33 Adsorption Autologous (Auto) 15

34 Adsorption Allogeneic (Allo) 10

35 Adsorption Rabbit Erythrocyte Stroma (RESt) (Cold Auto) 5

36 ABO/Rh Grouping 5

37 Antibody Screen 5

38 Platelet Crossmatch (Test) 20

39 Plateletpheresis, HLA Matched 5

40 Platelet Antibody Screen 10

41 HLA Antibody Screen 10

42 Patient HLA (A,B) Typing for HLA Platelet Selection 10

43 HPA-1a Antigen Screen 1

44 Molecular Genotype (HPA) 1

Added: Mar 22, 2017 2:37 pm THIS SOURCES SOUGHT/REQUEST FOR INFORMATION (RFI) IS ISSUED SOLELY FOR INFORMATION AND PLANNING PURPOSES ONLY, AND DOES NOT CONSTITUTE A SOLICITATION. THE SUBMISSION OF PRICING, CAPABILITIES FOR PLANNING PURPOSES, AND OTHER MARKET INFORMATION IS HIGHLY ENCOURAGED AND ALLOWED UNDER THIS SOURCES SOUGHT/RFI IN ACCORDANCE WITH (IAW) FAR 15.201(e).

DISCLAIMER

This Sources Sought/RFI is issued solely for information and planning purposes only, and does not constitute a solicitation. All information received in response to this Sources Sought/RFI that is marked as proprietary will be handled accordingly. IAW FAR 15.201(e), responses to this notice are not offers, and cannot be accepted by the U.S. Government to form a binding contract. Responders are solely responsible for all expenses associated with responding to this Sources Sought/RFI.

SOURCES SOUGHT/RFI DESCRIPTION

This is NOT a solicitation announcement. This is a Sources Sought/RFI only. The purpose of this Sources Sought/RFI is to gain knowledge of potential qualified sources and their size classifications relative to North American Industry Classification System (NAICS) code 621991 (size standard of $32.5 million). Responses to this sources sought/RFI will be used by the Government to make appropriate acquisition decisions. After review of the responses to this Sources Sought/RFI, a solicitation announcement may be published. Responses to this Sources Sought Synopsis/RFI are not considered adequate responses for a solicitation announcement.

The Department of Veterans Affairs (VA), VISN 21 Network Contracting Office, is seeking sources that can provide Human Blood Products. Emergent orders must be delivered to the San Francisco VA Medical Center within one hour of an order, deliveries must be made three-hundred and sixty-five days per year, and a supplier must be able to supply the specific items as follows:



Item

Number



Item Description

Estimated Quantity

Per Year

1

Leukocyte reduced Red Blood Cells(RBCs)

2,000

2

RBCs, Washed

25

3

RBCs, Irradiated

200

4

RBCs, Autologous

20

5

RBCs, Thawed

12

6

RBCs, Directed

6

7

Fresh Frozen Plasma (FFP)

900

8

Platelet, single donor (SD) Apheresis

500

9

Pooled Cryoprecipitate (Cryo)

75

10

Rh Immune Globulin (Rhlg)

2

11

Screening for Negative Blood per Antigen

100

12

Irradiated Units

400

13

Screening for Cytomegalovirus (CMV) Negative Blood

20

14

Antibody Identification

30

15

Enzyme Panel

20

16

Select Cell Panel

20

17

Absorption/Elution with Panel

15

18

Inhibition/Panel

5

19

Chloroquine Treatment

5

20

Extended Phenotyping

30

21

Phenotyping, Genotyping Whole Blood or Red Cell Mass

32

22

Plateletpheresis, Crossmatched

10

23

Screening for Historically Antigen Negative Blood per Antigen

200

24

Crossmatched Platelet Donor Recruitment

30

25

Transporation Surcharge for (Statim) STAT Orders

200

26

STAT Off Hours Surcharge

40

27

Volume-reduced cellular products

10

28

Dithiothreitol (DTT) Screen

25

29

DTT panel

10

30

RBC Genotype [Human Erytrocyte Antigen (HEA) BeadChip Assay or similar]

5

31

Drug Study

5

32

Direct Antiglobulin Test

5

33

Adsorption Autologous (Auto)

15

34

Adsorption Allogeneic (Allo)

10

35

Adsorption Rabbit Erythrocyte Stroma (RESt)(Cold Auto)

5

36

ABO/Rh Grouping

5

37

Antibody Screen

5

38

Platelet Crossmatch (Test)

20

39

Plateletpheresis, HLA Matched

5

40

Platelet Antibody Screen

10

41

HLA Antibody Screen

10

42

Patient HLA (A,B) Typing for HLA Platelet Selection

10

43

HPA-1a Antigen Screen

1

44

Molecular Genotype (HPA)

1



The information identified above is intended to be descriptive, not restrictive, and to indicate the quality of the supplies/services that will be satisfactory. It is the responsibility of the interested source to demonstrate to the Government that the interested parties can provide the supplies/services that fulfill the required specifications.

If you are interested, and are capable of providing the sought out supplies/services, please provide the requested information as well as the information indicated below. Responses to this notice/RFI should include company name, address, point of contact, size of business pursuant to the following questions:

Please indicate the size status and representations of your business, such as, but not limited to: Service Disabled Veteran Owned Small Business (SDVOSB), Veteran Owned Small Business (VOSB), Hubzone, Woman Owned Small Business (WOSB), Large Business, etc.).

Is your company considered small under the NAICS code identified under this RFI?

Are you the manufacturer or authorized distributor/reseller of the items being referenced above (or equivalent product/solution)?

What is the manufacturing country of origin of these items?

If you are a small business, and you are an authorized distributor/reseller for the items identified above (or equivalent product/solution), do you alter; assemble; modify; the items requested in any way? If you do, state how and what is altered; assembled; modified?

Does your company have an FSS contract with GSA or the NAC, or are you a contract holder with NASA SEWP or any other federal contract? If so, please provide the contract type and number.

If you are an FSS, GSA/NAC, or NASA SEWP contract holder, or other federal contract holder, are the referenced items/solutions available on your schedule/contract?

Please provide general pricing for your products/solutions for market research purposes, and state whether the pricing is from an FSS, GSA/NAC, or NASA SEWP schedule/contract or is open market pricing.

Please submit your capabilities in regards to the salient characteristics being provided, and any information pertaining to equal to items to establish capabilities for planning purposes. Submissions shall show clear, compelling, and convincing evidence that all equal to items meet all required salient characteristics.

Responses to this notice shall be submitted via email to Susanne.Christen@va.gov. Telephone responses shall not be accepted. Responses must be received no later than Friday, April 7, 2017 at 8 a.m. Eastern Standard Time. If a solicitation is issued it shall be announced at a later date, and all interested parties must respond to that solicitation announcement separately from the responses to this Sources Sought/RFI. Responses to this notice are not a request to be added to a prospective bidders list, or to receive a copy of the solicitation.